title: Rotavirus vaccine: a review.
abstract: Worldwide, large proportion i.e., 37% of deaths due to diarrhea in young children is attributed to rotavirus. A monovalent P1A[8] G1 vaccine and a pentavalent bovine-human reassortant vaccine human rotavirus vaccine had shown good clinical efficacy without any increase in intussusception among vaccine recipients. WHO recommends that the first dose of rotavirus vaccine should be administered to infants up to age of 6-15 weeks irrespective of the prior history of rotavirus infection and the maximum age for administering the last dose of the vaccine should be 32 weeks. Booster doses are not recommended. The current update reviews the issues related to rotavirus vaccines and their usages like milestones in the development of rotavirus vaccines, concerns regarding their efficacy and cost-effectiveness, immunity after natural infection, potential for changes in virus strains, current recommendations, post marketing surveillance, and future challenges and scope for further research regarding rotavirus vaccines.
authors.forename: Goel Manish
authors.initials: GM
authors.lastname: Kumar
authors.forename: Kumar
authors.initials: K
authors.lastname: Arun
authors.forename: Jain Ram
authors.initials: JR
authors.lastname: Bilas
authors.forename: Jain
authors.initials: J
authors.lastname: Ruchi
authors.forename: Khanna
authors.initials: K
authors.lastname: Pardeep
authors.forename: Siwach
authors.initials: S
authors.lastname: Pradeep
mesh_terms: D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007443:Intussusception / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage
chemical_list: D022243:Rotavirus Vaccines; D014614:Vaccines, Synthetic